Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Patrick G. Enright sold 9,000 shares of the firm’s stock in a transaction dated Monday, December 11th. The stock was sold at an average price of $139.73, for a total value of $1,257,570.00. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Shares of Jazz Pharmaceuticals PLC (NASDAQ JAZZ) opened at $135.53 on Friday. The company has a debt-to-equity ratio of 0.63, a current ratio of 3.10 and a quick ratio of 2.94. Jazz Pharmaceuticals PLC has a 1-year low of $104.82 and a 1-year high of $163.75. The company has a market capitalization of $8,123.29, a P/E ratio of 17.00, a price-to-earnings-growth ratio of 0.87 and a beta of 0.98.
Several analysts recently commented on the company. J P Morgan Chase & Co reaffirmed a “buy” rating and set a $190.00 target price on shares of Jazz Pharmaceuticals in a report on Monday, September 18th. Royal Bank of Canada reaffirmed a “buy” rating and set a $210.00 target price on shares of Jazz Pharmaceuticals in a report on Friday, September 15th. BMO Capital Markets reaffirmed a “buy” rating and set a $196.00 target price on shares of Jazz Pharmaceuticals in a report on Wednesday, September 20th. Morgan Stanley assumed coverage on Jazz Pharmaceuticals in a report on Thursday, October 5th. They set an “equal weight” rating and a $155.00 target price on the stock. Finally, Goldman Sachs Group assumed coverage on Jazz Pharmaceuticals in a report on Thursday, September 28th. They set a “neutral” rating and a $165.00 target price on the stock. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and nineteen have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus target price of $181.28.
Jazz Pharmaceuticals Company Profile
Jazz Pharmaceuticals, Inc is a specialty pharmaceutical company focusing on the development and commercialization of pharmaceutical products to meet unmet medical needs in neurology and psychiatry. As of December 31, 2009, the Company markets two products: Xyrem (sodium oxybate) for the treatment of both cataplexy and excessive daytime sleepiness in patients with narcolepsy; and Luvox CR (fluvoxamine maleate) for the treatment of both obsessive compulsive disorder and social anxiety disorder.
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.